These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25458914)

  • 41. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis B core-based virus-like particles to present heterologous epitopes.
    Roose K; De Baets S; Schepens B; Saelens X
    Expert Rev Vaccines; 2013 Feb; 12(2):183-98. PubMed ID: 23414409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Companies Claim to Fame and their scientific challenges in vaccine development.
    Boon L
    Immunol Lett; 2009 Feb; 122(2):123-5. PubMed ID: 19101592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.
    Karch CP; Doll TAPF; Paulillo SM; Nebie I; Lanar DE; Corradin G; Burkhard P
    J Nanobiotechnology; 2017 Sep; 15(1):62. PubMed ID: 28877692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.
    Valero-Pacheco N; Pérez-Toledo M; Villasís-Keever MÁ; Núñez-Valencia A; Boscó-Gárate I; Lozano-Dubernard B; Lara-Puente H; Espitia C; Alpuche-Aranda C; Bonifaz LC; Arriaga-Pizano L; Pastelin-Palacios R; Isibasi A; López-Macías C
    PLoS One; 2016; 11(2):e0150146. PubMed ID: 26919288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
    Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
    Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant influenza A viruses as vaccine vectors.
    Gerlach T; Elbahesh H; Saletti G; Rimmelzwaan GF
    Expert Rev Vaccines; 2019 Apr; 18(4):379-392. PubMed ID: 30777467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Lindsay BJ; Bonar MM; Costas-Cancelas IN; Hunt K; Makarkov AI; Chierzi S; Krawczyk CM; Landry N; Ward BJ; Rouiller I
    Vaccine; 2018 Apr; 36(16):2147-2154. PubMed ID: 29550194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
    Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A
    Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new boost for malaria vaccines.
    Pouniotis DS; Proudfoot O; Minigo G; Hanley JC; Plebanski M
    Trends Parasitol; 2004 Apr; 20(4):157-60. PubMed ID: 15099550
    [No Abstract]   [Full Text] [Related]  

  • 54. Challenges in the development of egg-independent vaccines for influenza.
    Trombetta CM; Marchi S; Manini I; Lazzeri G; Montomoli E
    Expert Rev Vaccines; 2019 Jul; 18(7):737-750. PubMed ID: 31265333
    [No Abstract]   [Full Text] [Related]  

  • 55. Malaria vaccines: are seven antigens better than one?
    Stanley SL
    Lancet; 1998 Oct; 352(9135):1163-4. PubMed ID: 9777828
    [No Abstract]   [Full Text] [Related]  

  • 56. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines.
    Ward BJ; Landry N; Trépanier S; Mercier G; Dargis M; Couture M; D'Aoust MA; Vézina LP
    Vaccine; 2014 Oct; 32(46):6098-106. PubMed ID: 25240757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
    Crevar CJ; Carter DM; Lee KY; Ross TM
    Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.
    Thompson CM; Petiot E; Lennaertz A; Henry O; Kamen AA
    Virol J; 2013 May; 10():141. PubMed ID: 23642219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.